Burosumab in Unidentifiable Tumor-Induced Osteomalacia.

Tumor-induced osteomalacia (TIO) can be challenging due to underlying tumors being either unresectable or unidentifiable. Burosumab, an anti-FGF23 monoclonal antibody, has been proven to be effective in treating TIO but is currently not subsidized for this indication in Australia. Our experience suggests that burosumab should be considered a first-line treatment.